QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: jpet.104.078014v1 313/1/112    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Abad-Merin, M. J. Articles by Ferrer-Montiel, A. Search for Related Content PubMed PubMed Citation Articles by Abad-Merin, M. J. Articles by Ferrer-Montiel, A.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Trimers of N-Alkylglycines Are Potent Modulators of the Multidrug Resistance Phenotype

Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Alicante, Spain (M.J.A.-M., J.A.F., A.F.-M.); Department of Biological Organic Chemistry, Institut d'Investigacions Quimiques i Ambientals de Barcelona (Consejo Superior de Investigaciones Cientificas), Barcelona, Spain (N.C., I.M., A.M.); and Fundación Valenciana de Investigaciones Biomédicas, Consejo Superior de Investigaciones Cientificas, València, Spain (E.P.-P.)

The multidrug resistance (MDR) phenotype is considered a major cause of the failure of cancer chemotherapy. The acquisition of MDR is usually mediated by the overexpression of drug efflux pumps such as glycoprotein P (P-gp) or multidrug resistance-related protein 1 (MRP1). Thus, the identification, validation, and development of compounds that mitigate the MDR phenotype by modulating the activity of these transport proteins is an important yet elusive target. Here, we have addressed this issue and screened an N-trialkylglycine-based combinatorial library composed of 5120 compounds to search for modulators of the MDR phenotype. The screening identified 20 trimers of N-alkylglycine that increased the intracellular accumulation of daunomycin (DNM) in drug-resistant L1210R tumor cells that overexpressed the P-gp. These compounds seem to act as P-gp antagonists, as evidenced by the augmentation of DNM accumulation in the L1210^P-gp cell line, a drug-sensitive L1210 cell stably expressing the murine P-gp protein. Similarly, several of the active N-trialkylglycines also produced an increment in DNM uptake in human HL60R cells, which primarily express the MRP1 protein. Trialkylglycines notably sensitized L1210R and HL60R tumor cells to DNM with a potency that rivaled that of verapamil. These findings provide new molecular scaffolds for the development of effective chemosensitizers against the MDR phenotype that, in due turn, could be used as adjuvant drugs in cancer chemotherapy.

Address correspondence to: Dr. Antonio Ferrer-Montiel, Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Ed. Torregaitán, Av. de la Universidad s/n, 03202 Elche (Alicante), Spain. E-mail: aferrer{at}umh.es